美股異動|Grab夜盤大升超11% Q3實現扭虧為盈並上調全年業績指引
新加坡互聯網公司Grab Holdings(GRAB.US)美股夜盤升超11.6%,報4.89美元。消息面上,Grab公佈第三季度業績,營收同比增長17%至7.16億美元,高於分析師預期的6.97億美元;期內實現扭虧為盈,錄得淨利潤1500萬美元,而去年同期錄得虧損9900萬美元;調整後EBITDA為9000萬美元,同比大幅增長224%。期內GMV同比增長15%。
此外,該公司上調全年業績指引,預計營收將介於27.6億至27.8億美元之間,此前預期為27億至27.5億美元;預計調整後EBITDA將介於3.08億至3.13億美元之間,此前預期為2.5億至2.7億美元。(格隆匯)

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.